Clinic Roundup
• Peregrine Pharmaceuticals Inc., of Tustin, Calif., said it reached an agreement with the FDA on the design of a single registration trial testing Cotara in patients with recurrent glioblastoma multiforme.
• Peregrine Pharmaceuticals Inc., of Tustin, Calif., said it reached an agreement with the FDA on the design of a single registration trial testing Cotara in patients with recurrent glioblastoma multiforme.